The involvement of LDL - Associated phospholipase A2 in atherogenesis

Pharmacology Reviews and Communications

Volumn 8, Issue 4, 1996, Pages 309-315

  Macphee, Colin H ^a   Milliner, Kevin ^a   Moores, Kitty ^a   Tew, David G ^a  

^a The Frytke ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3042941139     PISSN: 10288945     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Berliner, J. A. and Haberland, M. A. (1993). The role of low density lipoprotein in atherogenesis, Current Opinion in Lipidology, 4, 373-381.
2. Blencowe, C., Hermetter, A., Kostner, G. M. and Deigner, H. P. (1995). Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein, J. Biol. Chem., 270, 31151-31157.
3. Chait, A. and Heinecke, J. W. (1994). Lipoprotein modification: cellular mechanisms, Current Opinion in Lipidology, 5, 365-370.
4. Cousens, L., Eberhardt, C. D., Gray, P., Le Trong, H., Tjoelker, L. W. and Wilder, C. L. (1995). Platelet-activating factor acetylhydrolase. International Patent Application PCT/US94/11340: 46-48.
5. Cowan, C. L. and Steffen, R. P. (1995). Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium-derived nitric oxide and endothelium-derived hyperpolarising facto independent of protein kinase C activation, Arterioscler. Thromb. Vasc. Biol., 15, 2290-2297.
6. Croft, K. D., Williams, P., Dimmitt, S., Abu-Amsha, R. and Beilen, L. J. (1995). Oxidation of low density lipoproteins: effect of antioxidant content, fatty acid composition and intrinsic phospholipase activity on susceptibility to metal ion-induced oxidation, Biochim. Biophys. Acta, 1254, 250-256.
7. Davies, M. J. and Woolf, N. (1993). Atherosclerosis: what is it and why does it occur? Br. Heart J., 69 (Suppl.), S3-S11.
8. de Graaf, J., Hak-Lemmers, H. L. M., Hectors, M. P. C., Demacker, P. N. M., Hendriks, J. C. M. and Stalenhoef, A. F. H. (1991). Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects, Arterio. Thrombosis, 11, 298-306.
9. Esterbauer, H., Jurgens, G., Quehenberger, O. and Koller, E. (1987). Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes, J. Lipid Res., 28, 495-509.
10. Flavahan, N. A. (1992). Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity, Circulation, 85, 1927-1938.
11. Graham, R. M., Stephens, C. J., Sturm, M. J. and Taylor, R. R. (1992). Plasma platelet-activating factor degradation in patients with severe coronary artery disease, Clin. Sci., 82, 535-541.
12. Heery, J. M., Kozak, M., Stafforini, D. M., Jones, D. A., Zimmerman, G. A., McIntyre, T. M. and Prescott, S. M. (1995). Oxidatively modified LDL contains phospholipids with platelet activating factor-like activity and stimulates the growth of smooth muscle cells, J. Clin. Invest., 96, 2322-2330.
13. Hofmann, B., Ruhling, K., Spangenberg, P. and Ostermann, G. (1989). Enhanced degradation of platelet-activating factor in serum from diabetic patients, Haemostasis, 19, 180-184.
14. Holvoet, P. and Collen, D. (1994). Oxidised lipoproteins in atherosclerosis and thrombosis, FASEB J., 8, 1279-1284.
15. Karabina, S. P., Liapikos, T. A., Grekas, G., Goudevenos, J. and Tselepis, A. D. (1994). Distribution of PAF-acetylhydrolase activity in human plasma low density lipoprotein subfractions, Biochim. Biophys. Acta, 1213, 34-38.
16. Khan, B. V , Parthasarathy, S. S., Alexander, R. W. and Medford, R. M. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells, J. Clin. Invest., 1995, 1262-1270.
17. Kugiyama, K., Kerns, S. A., Morrisett, J. D., Roberts, R. and Henry, P. D. (1990). Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low density lipoproteins, Nature, 344, 160-162.
18. Kume, N., Cybulsky, M. I. and Gimbrone, M. A. (1992). Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells, J. Clin. Invest., 90, 1138-1144.
19. Kume, N. and Gimbrone, Jr., M. A. (1994). Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells, J. Clin. Invest., 93, 907-911.
20. Liu, S.-Y-, Lu, X., Choy, S., Dembinski, T. C., Hatch, G. M., Mymin, D., Shen, X., Angel, A., Choy, P. C. and Man, R. Y. K. (1994). Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation, Cardiovascular Res., 28, 1476-1481.
21. Miwa, M., Miyake, T., Yamanaka, T., Sugatani, J., Suzuki, Y., Sakata, S., Araki, Y. and Matsumoto, M. (1988). Characterisation of serum platelet-activating factor acetylhydrolase, J. Clin. Invest., 82, 1983-1991.
22. Nakano, T., Raines, E. W., Abraham, J. A., Klagsbrun, M. and Ross, R. (1994). Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth facto-like growth factor mRNA in human monocytes. Proc. Natl. Acad. Sci. USA, 91, 1069-1073.
23. Ostermann, G., Ruhling, K., Zabel-Langhennig, R., Winkler, L., Schlag, B. and Till, U. (1987). Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor, Thrombosis Res., 47, 279-285.
24. 2 activity in endothelial cell-induced modification of low density lipoprotein, Proc. Natl. Acad. Sci. USA, 82, 3000-3004.
25. Quinn, M. T., Parthasarathy, S and Steinberg, D. (1988). Lysophosphatidylcholine: a chemotacnc factor for human monocytes and its potential role in atherogenesis, Proc. Natl. Acad Sci. USA, 85, 2805-2809.
26. Satoh, K., Imaizumi, T , Kawamura, Y., Yoshida, H., Takamatsu, S. and Takamatsu, M. (1989). Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension, Prostaglandins, 37, 673-682.
27. Satoh, K., Yoshida, H., Imaizumi, T. A., Takamatsu, S. and Mizuno, S. (1992). Platelet activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke, Stroke, 23, 1090-1092.
28. Snyder, F. (1995). Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes, Biochim. Biophys. Acta, 1254, 231-249.
29. Stafforini, D. M., Elstad, M. R., McIntyre, T M., Zimmerman, G. A. and Prescott, S. M. (1990). Human macrophages secrete platelet-activating factor acetylhydrolase, J. Biol. Chem., 265, 9682-9687.
30. Stafforini, D. M., Zimmerman, G. A., McIntyre, T. M. and Prescott, S. M. (1993). The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein, Trans. Assoc. Amer. Phys., 105, 44-63.
31. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C. and Witzum, J. L. (1989). Beyond cholesterol: Modifications of of low density lipoprotein that increases its atherogenicity, N. Engl. J. Med., 320, 915-924.
32. Steinbrecher, U. P. and Pritchard, P. H. (1989). Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet activating factor acetylhydrolase, J. Lipid Res., 30, 305-315.
33. Stremler, K. E., Stafforini, D. M., Prescott, S. M. and McIntyre, T. M. (1991). Human platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates, J. Biol. Chem., 266, 11095-11103.
34. Sugiyama, S., Kugiyama, K., Ohgushi, M., Fujimoto, K. and Yasue, H. (1994). Lysophosphatidylcholine in oxidised LDL increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries, Circ. Res., 74, 565-575.
35. Tew, D. G., Southan, C., Rice, S. Q. J., Lawrence, M. P., Li, H., Saul, H. F., Moores, K., Gloger, I. S. and Macphee, C. H. (1996). Purification, properties, sequencing and cloning of a lipoprotein associated, serine dependent phospholipase which is involved in the oxidative modification of low density lipoproteins, Arterioscler. Thromb. Vasc. Biol., 16, 591-599.
36. Tjoelker, L. W., Wilder, C., Eberhardt, C., Stafforini, D. M., Dietsch, G., Schimp, B., Hooper, S., Trong, H. L., Cousens, L. S., Zimmerman, G. A., Yamada, Y., McIntyre, T. M., Prescott, S. M. and Gray, P. W. (1995). Anti-inflammatory properties of a platelet-activating factor acetylhydrolase, Nature, 374, 549-553.
37. Venable, M. E., Zimmerman, G. A., McIntyre, T. M. and Prescott, S. M. (1993). Platelet-activating factor: a phospholipid autocoid with diverse actions, J. Lipid Res., 34, 691-702.
38. Watson, A. D., Navab, M., Hama, S. Y., Sevanian, A., Prescott, S. M., Stafforini, D. M., McIntyre, T. M., La Du, B. N., Fogelman, A. M. and Berliner, J. A. (1995). Effect of platelet-activating factor acetylhydrolase on the formation and action of minimally oxidised low density lipoprotein, J. Clin. Invest., 95, 774-782.
39. Watson, A. D , Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. M., Fogelman, A. M. and Navab, M. (1995). Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low density lipoprotein, J. Clin. Invest., 96, 2882-2891.